Moderna is falling today: what traders are watching (December 23)

Traders Union
All News
Financial News
Moderna Slides 7.48% to $32.29 Today

Highlights

Moderna received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its mNEXSPIKE COVID-19 vaccine in individuals aged 12 and older.
Moderna's CEO retained expiring stock options set to expire in February 2026, signaling confidence in the company's future performance.
Thrivent Financial for Lutherans substantially increased its stake in Moderna during the second quarter, indicating rising institutional investor interest.

Investor confidence rises after upbeat regulatory news and insider moves

Moderna recently secured a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending marketing authorization for its mNEXSPIKE vaccine to prevent COVID-19 in individuals aged 12 and older. There was notable insider activity as the company's CEO held on to expiring stock options set to expire in February 2026. Additionally, Thrivent Financial for Lutherans substantially increased its stake in the company during the second quarter.

Anton Kharitonov, expert at Traders Union, sees persistent risk despite Moderna’s bullish arrangement above all key moving averages. He notes the daily 7.48% drop exposes intraday weakness and divergence with positive trend signals. The analyst points out that insider activity from the CEO and institutional inflows offer only superficial support against fragile price action. He observes that overbought oscillators and a close near the daily low highlight exhaustion risk and challenge bullish momentum. Kharitonov warns that failing $29.11 support could open a path to deeper declines. "A defensive stance is crucial at these levels, as sellers are clearly dominating the intraday narrative."

Viktoras Karapetjanc, expert at Traders Union, is confident the longer-term bullish structure remains intact for Moderna, as price stays above all major moving averages. He highlights strong institutional interest, positive regulatory momentum from the EMA, and CEO’s vote of confidence as meaningful drivers. Karapetjanc sees the recent volatility as a shakeout that may create new setups for forward-looking investors. He believes resistance at $33.00 — $33.50 offers a trigger for further growth if broken. "With multi-level support and institutional backing, I expect the market will reward patient bulls on the next breakout."

Jainam Mehta, market strategist, observes a tactical divergence between the underlying daily bullish trend and intraday seller pressure. He notes that a potential reversal setup could emerge if price holds above the $29.11 support, but sees elevated risk of further downside without a decisive close above $33.00. Mehta suggests that contrarian entries may arise if momentum and sentiment reset lower after this volatility. "Traders should watch for a flush below support or a sharp reclaim of resistance as the next actionable signal."

Divergence emerges as bullish trends meet overbought intraday signals

The current price of $32.29 is above the MA-20 at $28.45, MA-50 at $26.71, and MA-200 at $27.49, supporting a bullish structure for short-, medium-, and long-term trends. Immediate dynamic support sits near the Ichimoku Kijun at $29.11, while resistance is likely at the psychologically significant $33.00 level or the MA-5 near $32.49. Momentum readings are mixed: the daily MACD and ADX suggest buying interest, but several oscillators warn of overbought conditions, including Stoch RSI and CCI. Daily BBP points to an overbought scenario, but the price has dropped 7.48% today, with no meaningful gap at the open and a close near the daily low, reflecting high volatility with sellers dominating intraday. This drop and pressure after opening contradict bullish D1 momentum signals, demonstrating clear divergence between intraday weakness and underlying daily trends with some oscillators flagging risk of exhaustion.

Previously it was reported that Moderna displayed strong bullish momentum across all timeframes as it traded well above major moving averages, with oscillators like RSI and CCI indicating significant overbought conditions. Despite daily price action turning lower and sellers pressuring the stock intraday, core indicators such as MACD and ADX continued to support a bullish trend, though some momentum signals pointed to possible exhaustion.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.